CDEK
← All drugs Report issue

tapinarof

Trade name: Vtama

Small moleculeapproved

Approved

May 23, 2022

Tapinarof, also known as benvitimod and sold under the brand name Vtama among others, is a medication used for the treatment of plaque psoriasis. The medication is applied to the skin. Besides its use in medicine, tapinarof is a naturally occurring compound found in bacterial symbionts of nematodes which has antibiotic properties. — Wikipedia

Clinical trial activity

31 trials · 18 clinical orgs · 2 marketing orgs

Phase 1
7
Phase 2
19
Phase 3
12
Phase 4
4

Earliest trial started Mar 1, 2008 (NCT00837551)

Timeline

2000s

  1. Jan 1, 2008

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2009

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2017

    Earliest Phase 3 Sponsor(trial)

2020s

  1. May 23, 2022

    Roivant Sciences, Inc. — Earliest FDA Approval

  2. May 23, 2022

    Roivant Sciences, Inc. — Marketing Organization

  3. May 23, 2022

    Roivant Sciences, Inc. — NDA Secondary Org

  4. May 23, 2022

    Roivant Sciences, Inc. — NDA Organization

  5. May 23, 2022

    Organon — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedMay 23, 2022

Chemistry & pharmacology

Loading structure…

SMILES

CC(C)c1c(O)cc(/C=C/c2ccccc2)cc1O
Mol. weight
254.33 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Topical
Availability
Prescription Only

Oral

No

Parenteral

No

Topical

Yes

First in class

Sources

Also known as

  • 2-isopropyl-5-(2-phenylethenyl)benzene-1,3-diol
  • 5-(2-phenylethenyl)-2-isopropyl-1,3-benzenediol
  • benvitimod
  • gsk2894512
  • gsk2894512
  • wbi-1001
  • wbi-1001
  • wbi-1001

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07265479Phase 3Dec 31, 2025Organon
NCT06661213Early Phase 1 (Phase 1)Dec 31, 2024Northwestern University
NCT06742957Phase 3Dec 17, 2024Teva
NCT06561321Phase 2Oct 26, 2024Indiana University, Roivant Sciences, Inc.
NCT05981118Phase 2/Phase 3 (Phase 3)Jul 15, 2024Roivant Sciences, Inc., Wake Forest University
NCT05789576Phase 4Mar 13, 2023Roivant Sciences, Inc.
NCT06103695Phase 4Feb 27, 2023Windsor Dermatology
NCT05680740Phase 4Jan 12, 2023Roivant Sciences, Inc.
NCT05326659N/AApr 30, 2022Peking University, Zhonghao Pharmaceutical
NCT05326672Phase 3Apr 30, 2022Peking University, Zhonghao Pharmaceutical
NCT05172726Phase 3Dec 2, 2021Roivant Sciences, Inc.
NCT05186805Phase 2Oct 29, 2021Roivant Sciences, Inc.
NCT05142774Phase 3Oct 28, 2021Roivant Sciences, Inc.
NCT05032859Phase 3Sep 23, 2021Roivant Sciences, Inc.
NCT05014568Phase 3Sep 1, 2021Roivant Sciences, Inc.
NCT05064748Phase 4Jun 1, 2021Peking University, Zhonghao Pharmaceutical
NCT04053387Phase 3Aug 31, 2019IQVIA, Roivant Sciences, Inc.
NCT04042103Phase 2Jul 23, 2019Roivant Sciences, Inc.
NCT03983980Phase 3Jun 6, 2019Roivant Sciences, Inc.
NCT03956355Phase 3May 21, 2019Roivant Sciences, Inc.
Showing 20 of 31 trials
Page 1 / 2

Organizations

Research & Development (18)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Roivant Sciences, Inc.For profit131132019
GlaxoSmithKlineFor profit8632013
InnovadermFor profit3022008
Peking UniversityAcademic/Hospital3332021
Welichem Biotech Inc.For profit3312008
Zhonghao PharmaceuticalFor profit3032021
PPDFor profit2022017
Stiefel LaboratoriesFor profit2212013
iCardiacFor profit1012017
Indiana UniversityAcademic/Hospital1112024
IQVIAFor profit1012019
Northwestern UniversityAcademic/Hospital1112024
OrganonFor profit1112025
Q2 solutionsFor profit1012017
Sponsor GmbHAcademic/Hospital1012009
TevaFor profit1112024
Wake Forest UniversityAcademic/Hospital1112024
Windsor DermatologyAcademic/Hospital1112023
18 organizations
Page 1 / 1

Marketing (4)

OrganizationOrg typeRelationshipDate
OrganonFor profitMKTGMay 23, 2022
Roivant Sciences, Inc.For profitMKTGMay 23, 2022
Roivant Sciences, Inc.For profitNDA2May 23, 2022
Roivant Sciences, Inc.For profitNDAMay 23, 2022